Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 63
- Development of new strategies for value-based care in chronic inflammatory bowel diseases.From5 Dec 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Gut functional and inflammatory disorders: biomarker and therapeutic target discovery (GUT-FIRE)From10 Jul 2023 → TodayFunding: IOF - mandates
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom1 Apr 2023 → TodayFunding: HORIZON.2.1 - Health
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Feb 2023 → TodayFunding: BOF - projects
- Characterization of triggers of post-operative recurrence in Crohn’s disease in both the external and luminal side of the intestineFrom1 Jan 2023 → TodayFunding: FWO research project
- Development of a gut-on-a-chip model for pre-clinical testing of drugs for inflammatory bowel diseaseFrom12 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Jun 2022 → TodayFunding: BOF - various
- Host-microbe interaction in intestinal homeostasis: unravelling the mechanisms involved in the onset of multiple inflammationrelated diseasesFrom1 Jan 2022 → TodayFunding: FWO EOS
- Histological healing in inflammatory bowel diseaseFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
891 - 900 of 1016
- Mucosal Healing and anti TNFs in IBD(2010)
Authors: Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Pages: 227 - 233 - The potential for disease modification in Crohn's disease(2010)
Authors: Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Pages: 79 - 85 - Efficacy of Infliximab in Refractory Pouchitis and Crohn's Disease-Related Complications of the Pouch: A Belgian Case Series(2010)
Authors: Marc Ferrante, Karel Geboes, Gert De Hertogh, Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Pages: 243 - 249 - Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease(2010)
Authors: Marie Joossens, Kristel Van Steen, Paul Rutgeerts, Séverine Vermeire
Pages: 58 - 67 - Likelihood ratio for Crohn's disease as a function of anti-Saccharomyces cerevisiae antibody concentration(2010)
Authors: Nathalie Vermeulen, Séverine Vermeire, Paul Rutgeerts, Xavier Bossuyt
Pages: 5 - 6 - Predicting the response to infliximab from trough serum levels(2010)
Authors: Paul Rutgeerts, Séverine Vermeire, Gert Van Assche
Pages: 7 - 8 - Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis(2010)
Authors: Ingmar Claes, Sarah Lebeer, Chong Shen, Gert De Hertogh, Dominique Bullens, Jan Ceuppens, Gert Van Assche, Séverine Vermeire, Paul Rutgeerts, Jos Vanderleyden, et al.
Pages: 306 - 314 - Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease)(2009)
Authors: Marc Ferrante, Paul Rutgeerts, Séverine Vermeire, Gert Van Assche
Pages: 504 - 508 - Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis(2009)
Authors: Ingrid Arijs, Roel Quintens, Kristel Van Steen, Gert De Hertogh, Katleen Lemaire, Marc Ferrante, Lieven Thorrez, Gert Van Assche, Séverine Vermeire, Karel Geboes, et al.
Pages: 1612 - 1619 - Efficacy of certolizumab pegol is not affected by baseline anti-infliximab antibody status in patients with Crohn's disease with secondary infliximab failure(2009)
Authors: W Sandborn, Séverine Vermeire, Geert D'Haens, J Colombel, R Fedorak, M Spehlmann, D Wolf, K Mitchev, C Jamoul, M Abreu, et al.
Pages: S452 - S452
Patents
1 - 10 of 10
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)